Skip to main content

Table 6 Prognostic factors for overall survival

From: Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

  Univariate analysis Multivariate analysis
Covariate P HR (95% CI) P HR (95% CI)
Sex (ref: Male) 0.0002 0.801 (0.713–0.899) 0.0003 0.792 (0.698–0.900)
Age (ref: < 75 years old) 0.0024 1.389 (1.123–1.717)
Histotype (ref: Other)
 LMS 0.0004 0.765 (0.659–0.888) 0.0010 0.765 (0.652–0.897)
 DLPS 0.0269 1.291 (1.030–1.619) 0.2034 1.171 (0.918–1.492)
 MPNST 0.1368 1.273 (0.926–1.751) 0.2183 1.234 (0.883–1.726)
 SS 0.4738 1.074 (0.883–1.307) 0.0764 1.206 (0.980–1.485)
 UPS 0.0061 1.347 (1.089–1.668) 0.1839 1.168 (0.929–1.469)
 Grade (ref: < 3) < 0.0001 1.692 (1.491–1.920) < 0.0001 1.687 (1.483–1.919)
 Number of metastatic sites (ref: 1) 0.0136 1.200 (1.038–1.387) 0.0009 1.305 (1.115–1.528)
 Liver metastasis (ref: no) 0.1056 0.891 (0.774–1.025)
 Locoregional treatment (ref: no) < 0.0001 0.412 (0.365–0.465) < 0.0001 0.400 (0.351–0.455)
 Clinical trial (ref: no) < 0.0001 0.750 (0.653–0.862) 0.0002 0.755 (0.651–0.877)
 Off-label drugs (ref: no) < 0.0001 0.791 (0.703–0.890)
 Anthracycline (ref: no) 0.0046 0.838 (0.741–0.947)
 Anthracycline in first line (ref: no) 0.0127 0.861 (0.765–0.968)
 Polychemotherapy in first line (ref: no) 0.0003 0.804 (0.715–0.902) 0.0023 0.822 (0.724–0.932)
  1. DLPS dedifferentiated liposarcomas, LMS leiomyosarcomas, MPNST malignant peripheral nerve sheath sarcomas, SS synovial sarcomas, UPS undifferentiated pleomorphic sarcomas